Purpose: Sirtuins (SIRTs) play a critical role in redox and metabolic regulation of the myocardium; however, the cardioprotective potential of SIRT5 in terms of infarct size (IS) reduction is still elusive. Herein, we employed the newly synthesized SIRT5-specific agonist, MC3215, developed by our group, to explore for the first time the pharmacological activation of SIRT5 as a target for cardioprotection. Methods and Results: In in vitro screening experiments, SIRT1 and SIRT5 agonists, namely, MC2606 and MC3215, at 1– 20 μ&Mgr; were added to cardiomyoblasts (H9c2) and human endothelial cells (EA.hy-926) during 24 h hypoxia/2 h reoxygenation (H/R). SIRT1 and SIRT5 agonists mitigated H/R injury. Male C57BL/6J mice underwent 30 min ischemia (I) followed by 2 h or 24 h reperfusion (R). Mice received vehicle, the SIRT1 or SIRT5 agonists at 20 and 30 mg/kg at the 20th min of ischemia, and IS was quantified via triphenyl-tetrazolium chloride staining (n=5– 7/group). MC3215-mediated SIRT5 activation reduced IS at 24 h R at 20mg/kg compared to controls (25.18± 2.7% vs 38.80± 4.7%). MC3215 treatment resulted in reduced protein malonylation in all experimental settings. Targeted mass-spectrometry-based metabolomics in the ischemic heart at the 10th min of R suggested increased fatty acid oxidation, as indicated by increased N3-Trimethyllysine and D-pantothenate. Concomitantly, molecular analysis indicated that the SIRT5 agonist activated AMPKα and Reperfusion Injury Salvage Kinase (RISK) pathway. Additionally, at 3 h reperfusion, MC3215 led to increased mitofusin 2 without altering apoptosis, paving towards improved mitochondrial dynamics. Co-administration of SIRT5 inhibitor, TW-37, abrogated MC3215-mediated cardioprotection. Conclusion: SIRT5 pharmacological agonism emerges as a novel cardioprotective target, leading to RISK pathway activation and mitochondria-related metabolic effects, converging at salvaging ischemic myocardium from I/R injury.

Cardioprotection through pharmacological activation of Sirtuin 5 in a murine model of acute myocardial infarction / Castiello, Carola; Efentakis, Panagiotis; Nikolaou, Panagiota-Efstathia; Symeonidi, Lydia; Chania, Christina; Barla, Ioanna; Akrani, Ifigeneia; Kostomitsopoulos, Nikolaos; Gikas, Evangelos; Thomaidis, Nikolaos; Mikros, Emmanuel; Kleinbongard, Petra; Fioravanti, Rossella; Zwergel, Clemens; Valente, Sergio; Mai, Antonello; Andreadou, Ioanna. - In: DRUG DESIGN, DEVELOPMENT AND THERAPY. - ISSN 1177-8881. - 19:(2025), pp. 5489-5505. [10.2147/dddt.s509337]

Cardioprotection through pharmacological activation of Sirtuin 5 in a murine model of acute myocardial infarction

Castiello, Carola;Fioravanti, Rossella;Zwergel, Clemens;Valente, Sergio;Mai, Antonello
;
2025

Abstract

Purpose: Sirtuins (SIRTs) play a critical role in redox and metabolic regulation of the myocardium; however, the cardioprotective potential of SIRT5 in terms of infarct size (IS) reduction is still elusive. Herein, we employed the newly synthesized SIRT5-specific agonist, MC3215, developed by our group, to explore for the first time the pharmacological activation of SIRT5 as a target for cardioprotection. Methods and Results: In in vitro screening experiments, SIRT1 and SIRT5 agonists, namely, MC2606 and MC3215, at 1– 20 μ&Mgr; were added to cardiomyoblasts (H9c2) and human endothelial cells (EA.hy-926) during 24 h hypoxia/2 h reoxygenation (H/R). SIRT1 and SIRT5 agonists mitigated H/R injury. Male C57BL/6J mice underwent 30 min ischemia (I) followed by 2 h or 24 h reperfusion (R). Mice received vehicle, the SIRT1 or SIRT5 agonists at 20 and 30 mg/kg at the 20th min of ischemia, and IS was quantified via triphenyl-tetrazolium chloride staining (n=5– 7/group). MC3215-mediated SIRT5 activation reduced IS at 24 h R at 20mg/kg compared to controls (25.18± 2.7% vs 38.80± 4.7%). MC3215 treatment resulted in reduced protein malonylation in all experimental settings. Targeted mass-spectrometry-based metabolomics in the ischemic heart at the 10th min of R suggested increased fatty acid oxidation, as indicated by increased N3-Trimethyllysine and D-pantothenate. Concomitantly, molecular analysis indicated that the SIRT5 agonist activated AMPKα and Reperfusion Injury Salvage Kinase (RISK) pathway. Additionally, at 3 h reperfusion, MC3215 led to increased mitofusin 2 without altering apoptosis, paving towards improved mitochondrial dynamics. Co-administration of SIRT5 inhibitor, TW-37, abrogated MC3215-mediated cardioprotection. Conclusion: SIRT5 pharmacological agonism emerges as a novel cardioprotective target, leading to RISK pathway activation and mitochondria-related metabolic effects, converging at salvaging ischemic myocardium from I/R injury.
2025
sirtuins; sirt5; myocardial ischemia/reperfusion injury; cardioprotection
01 Pubblicazione su rivista::01a Articolo in rivista
Cardioprotection through pharmacological activation of Sirtuin 5 in a murine model of acute myocardial infarction / Castiello, Carola; Efentakis, Panagiotis; Nikolaou, Panagiota-Efstathia; Symeonidi, Lydia; Chania, Christina; Barla, Ioanna; Akrani, Ifigeneia; Kostomitsopoulos, Nikolaos; Gikas, Evangelos; Thomaidis, Nikolaos; Mikros, Emmanuel; Kleinbongard, Petra; Fioravanti, Rossella; Zwergel, Clemens; Valente, Sergio; Mai, Antonello; Andreadou, Ioanna. - In: DRUG DESIGN, DEVELOPMENT AND THERAPY. - ISSN 1177-8881. - 19:(2025), pp. 5489-5505. [10.2147/dddt.s509337]
File allegati a questo prodotto
File Dimensione Formato  
Castiello_Cardioprotection_2025.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 8.96 MB
Formato Adobe PDF
8.96 MB Adobe PDF
Castiello_Suppl. mat._Cardioprotection_2025.pdf

accesso aperto

Note: supportinginfo
Tipologia: Altro materiale allegato
Licenza: Creative commons
Dimensione 1.36 MB
Formato Adobe PDF
1.36 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1742029
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 1
social impact